Linked Life Data

10975387

Source:http://linkedlifedata.com/resource/pubmed/id/10975387

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2000-12-4
pubmed:abstractText
The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL). Fifty two consecutive patients with HIV infection, aggressive NHL and CD4+ cells > or = 100 x 10(6)/l were included. The median CD4 cell count was 276 x 10(6)/l. Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic. Twenty-five patients had stage IV disease (bone marrow involvement in 7, and central nervous system in 9). Three cycles of ACVBP (doxorubicine, cyclophosphamide, vindesine, bleomycin, prednisolone) were given. A fourth cycle was delivered to patients in partial remission or with initial bulky disease. The induction was followed by three cycles of CVM (cyclophosphamide, etoposide, methotrexate). G-CSF 5 microg/kg was used at each cycle. Results showed that 37 patients (71%) achieved a complete remission. With a median follow-up of 74 months, 8 of them have relapsed. The median survival was 15 months and 34 patients have died (21 with NHL). The 4-year estimate survival was 33.9% (95% CI, 19.8%-47.4%). The Relative Dose-Intensity of the chemotherapy was 85% for doxorubicine and 87% for cyclophosphamide. In a multivariate analysis, homosexual men and patients with ECOG < 2 had a lower risk for death: RR = 0.32 (95% CI, 0.15-0.65) and RR = 0.36 (95% CI, 0.18-0.74), respectively. Achievement of complete remission was strongly associated with survival. In conclusion, it seems that in HIV-infected patients with NHL and a CD4 cell count above 100 x 10(6)/l, high complete remission rate and prolonged survival can be achieved with the intensive LNHIV-91 regimen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
87-95
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:10975387-Actuarial Analysis, pubmed-meshheading:10975387-Adult, pubmed-meshheading:10975387-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10975387-Bleomycin, pubmed-meshheading:10975387-CD4 Lymphocyte Count, pubmed-meshheading:10975387-Cyclophosphamide, pubmed-meshheading:10975387-Disease-Free Survival, pubmed-meshheading:10975387-Doxorubicin, pubmed-meshheading:10975387-Drug Evaluation, pubmed-meshheading:10975387-Etoposide, pubmed-meshheading:10975387-Female, pubmed-meshheading:10975387-Follow-Up Studies, pubmed-meshheading:10975387-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:10975387-Hospitalization, pubmed-meshheading:10975387-Humans, pubmed-meshheading:10975387-Lymphoma, AIDS-Related, pubmed-meshheading:10975387-Lymphoma, Non-Hodgkin, pubmed-meshheading:10975387-Male, pubmed-meshheading:10975387-Methotrexate, pubmed-meshheading:10975387-Middle Aged, pubmed-meshheading:10975387-Prednisone, pubmed-meshheading:10975387-Recurrence, pubmed-meshheading:10975387-Survival Rate, pubmed-meshheading:10975387-Treatment Outcome, pubmed-meshheading:10975387-Vindesine
pubmed:year
2000
pubmed:articleTitle
Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
pubmed:affiliation
Department of Immunology and Hematology, Hôpital St Louis, Paris, France.
pubmed:publicationType
Journal Article